Breast cancer is the second most common cancer worldwide. Symptoms include a breast lump, skin changes, nipple changes (including inversion or discharge), pain and axillary masses. Traditionally, breast cancer subtypes are based on the type of cell affected, and the level of spread. Ductal carcinoma is non-invasive and is derived from the milk duct, whereas invasive ductal carcinoma (IDC) has spread to nearby tissue. Invasive lobular carcinoma (ILC) is derived from the lobules that produce milk and has invaded nearby breast tissue. The most lethal form of breast cancer is metastatic breast cancer (mBC) that has spread to other parts of the body including the lungs, liver and brain.
Oestrogen plays a major role in breast cancer pathogenesis and the oestrogen pathway has become a major therapeutic target. Subsequently, breast cancers are now more often described by their molecular subtype, which is based primarily on the combination of receptors that they express. These receptors include the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2). For instance, HER2 positive breast cancers can be treated with trastuzumab, a hormone therapy which binds to the HER2 receptor to slow growth. Triple negative breast cancers lack all three receptors and are poor candidates for hormone therapy.
Breast cancer treatment may involve classical treatment strategies such as surgery, radiotherapy and chemotherapy, or more targeted treatments including immunotherapy, hormonal suppression and more recently, targeting medicines such as CDK4/6 inhibitors and PARP inhibitors (for patients with BRCA1 or BRCA2 DNA repair gene mutations).
Visit our Learning Zone on metastatic breast cancer which highlights the burden of disease, pathophysiology and treatment using CDK4/6 inhibitors.
Featured Learning Zones
Related news and insights
Improvement in progression-free survival (PFS) and objective response rate (ORR) was not observed with the addition of ipatasertib from Genentech/Roche to paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer , missing the primary and secondary end points of the phase III IPATunity130 trial for which results were presented during the 2020 European Society of Medical Oncology (ESMO) Virtual Congress.
Eli Lilly and Company announced Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (HR: 0.747; 95% CI: 0.598, 0.932; p = 0.0096).
Genentech, a member of the Roche Group announced that it presented the latest results from three Phase III studies from the Tecentriq (atezolizumab) clinical development program in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
You may be interested in...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease. IPF is more common in elderly patients and over time as healthy lung tissue is replaced by altered extracellular matrix (fibrosis) the alveolar architecture is destroyed, leading to decreased lung function and finally respiratory failure and death.
ICRMB 2021: International Conference on Reproductive Medicine and Biology
ICRMB 2021: 15. International Conference on Reproductive Medicine and Biology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Reproductive Medicine and Biology.
International Conference on Nephrology and Urology
ICNU 2021: 15. International Conference on Nephrology and Urology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nephrology and Urology.